Posted by SLS on June 14, 2012, at 1:28:04
In reply to Re: SLS.. An awsome xenobiologic that U DONT KNOW ABOU » SLS, posted by novelagent on June 13, 2012, at 17:05:50
> I doubt these atypicals coming up are going to do much more than be a me-too next to Latuda.
Any one atypical does not necessarily have to do much more than the others; just being different seems to be enough to produce a variability in treatment response. My bipolar depression responds better to Abilify than it does to Seroquel or Zyprexa. Adding Latuda did not help me at all. It felt very much like Geodon to me. For me, both Latuda and Geodon produced significant cognitive impairments that I did not see with the others. 5-HT7 antagonism might be an effective target for some people, but obviously not for all. Saphris is an interesting drug. It might be particularly well suited for treating bipolar mixed states. I don't see that happening with Latuda yet. It is suppose to be evaluated for this purpose soon, though.
> I would switch to Latuda, maybe add Aricept.
Aricept exacerbated my depression. Pro-cholinergics aren't for everyone. They can be depressing. Depression is listed as a possible side effect. However, I know one person for whom it produced a robust antidepressant effect.
> Aricept boosted my mood and cognition when I was on it.
This is a good thing. I hope it works equally well for you this time around.
> The research for Latuda is very solid.
How so? What, in particular, does the research indicate?
> It's the only antipsychotic on the market with a robust body of evidence demonstrating it helps cognition,
Again, for me, Latuda produced robust cognitive impairments and some dissociation. By comparison, Zyprexa helped my cognition and produced a significant antidepressant effect. Some people report thinking more clearly on Zyprexa, more so than with the other AAPs. Unfortunately, this is not the case with everyone.
> > Keep an eye out for a drug called cariprazine. It is the second in a series of DA D2/D3 receptor partial agonists like Abilify. I will probably ask my doctor to allow me to crossover to cariprazine from Abilify in an attempt to avoid weight-gain and elevated triglycerides. Perhaps it will be a cleaner drug with respect to cognition and memory. It may not be, but I would regret it if I weren't to give cariprazine a try. It is currently in phase III investigation, and is due to be approved within a year.
I bet cariprazine and Abilify display some potential for treating cocaine addiction - much like buprenorphine aids in the treatment of heroin addiction. The key here is partial agonism at the relevant receptors; D2/D3 dopamine receptors for cocaine and µ opioid receptors for heroin.
Some see things as they are and ask why.
I dream of things that never were and ask why not.
- George Bernard Shaw